J&J to buy cardiovascular technology Abiomed in $16.6B deal

Low costs expected to keep Obamacare interest high
1 November 2022
Strong RSV vaccine data lifts hopes after years of futility
1 November 2022
0

J&J to buy cardiovascular technology Abiomed in $16.6B deal

Johnson & Johnson will spend $16.6 billion to buy cardiovascular technology company Abiomed to strengthen its medical device division.

Comments are closed.